EGFR and adrenal cortex carcinoma: Calvo et al. reported a partial response lasting for over 1.5 years in an ACC patient treated with figitumumab in combination with the EGFR inhibitor dacomitinib and stable disease as best overall response in another ACC patient receiving the same treatment [37].